Pfizer Ltd Stock Price Today (NSE: PFIZER)

Pfizer Ltd

4493.509.60 (0.21%)
Market Open

Fundamental Score

...

Pfizer Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Pfizer Ltd share price today is 4493.50, down 0.21% on NSE/BSE as of 17 June 2026. Pfizer Ltd (PFIZER) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of 22.74K (Cr). The 52-week high for PFIZER share price is 5981.00 and the 52-week low is 4460.00. At a P/E ratio of 32.18x, PFIZER is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 16.40% and a debt-to-equity ratio of 0.01.

Pfizer Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
5035.40
Low
4493.50
Volume
22.9K
Change
-3.52%

Pfizer Ltd share price chart: -3.52% return over the past month. 52-week high ₹5981.00, 52-week low ₹4460.00.

Pfizer Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
4515.204545.004480.004514.5011.32K (Cr)
4580.004598.004500.104515.3017.97K (Cr)
4622.604671.704570.004598.5016.27K (Cr)
4622.604622.604622.604622.600.00 (Cr)
4669.004689.204610.904622.6012.89K (Cr)
4699.004700.004626.004641.8013.61K (Cr)
4689.904720.004658.304689.2011.56K (Cr)
4689.904755.004638.804670.8020.73K (Cr)
4748.004748.004609.804651.3028.67K (Cr)
4808.904816.204656.004687.6036.55K (Cr)

Pfizer Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
4580.004598.004480.004514.50-1.43%
4701.105035.404521.004598.50-2.18%
4746.105045.004648.004710.60-0.75%
4912.005008.004522.004720.50-3.90%
4550.005257.004460.005062.20+11.26%
4940.005002.204541.004563.60-7.62%
4976.005166.304855.204987.70+0.24%
5212.505339.004948.004975.00-4.56%
5200.005578.505101.005209.00+0.17%
5200.005292.004770.505036.00-3.15%
5246.005873.504915.005156.00-1.72%
5749.005896.005179.005194.50-9.65%

Returns & Performance

Average

Return on Equity (ROE)

16.40%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

21.62%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

31.81%

Average operating profit margin over 5 years

Dividend Yield

0.70%

Annual dividend as % of current share price

Pfizer Ltd Valuation Check

Poor

Price to Earnings (P/E)

32.18x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Large-cap
Established & liquid; typically steadier returns.

Shareholding Pattern

Excellent

Promoter Holding

63.92%

% shares held by company founders/management

Poor

FII Holding

2.60%

% shares held by foreign institutional investors

Good

DII Holding

17.11%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Good

Profit Growth (Quarterly YoY)

19.37%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

9.13%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

1.18%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

4.68%

Earnings per share growth over 5 years

Poor

Net Profit Growth (5-Year CAGR)

4.68%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.01x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

99.16x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

2.43K (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Pfizer Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of PFIZER across key market metrics for learning purposes.

Positive Indicators

8 factors identified

Strong Return on Equity (16.40%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (21.62%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (31.81%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Conservative Debt Levels (D/E: 0.01)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (99.16x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Strong Cash Generation (₹2429.75 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (63.92%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

3 factors identified

Limited Growth History (1.18% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Weak Earnings Growth (4.68% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Stagnant Profit Growth (4.68% CAGR)

Observation: Limited 5-year profit growth trajectory.

Analysis: Low profit growth may indicate scalability challenges or market maturity.

Pfizer Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Pfizer Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
55/100
4494
₹22739.35
32.2
Average
16.40%
Good
21.62%
Excellent
0.0
Excellent
4.68%
Average
1.18%
Average
0.70%
65.2/100
1882
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4460
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1335
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2287
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2493
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Pfizer Ltd PE Ratio History

Historical price-to-earnings ratio for PFIZER — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 2025167.79₹4987.7029.7x
FY 2024120.51₹5281.5043.8x
FY 2023136.38₹4268.9531.3x
FY 2022133.89₹4431.7033.1x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Pfizer Ltd Dividend History

Annual cash dividends paid by PFIZER — dividend yield 0.70%

Financial YearDividends Paid (₹ Cr)
FY 2025160.25 Cr
FY 2024183.43 Cr
FY 2023297.21 Cr
FY 2022159.74 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Pfizer Ltd Quarterly Performance

Latest quarterly metrics for PFIZER — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

9.13%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

19.37%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

1.18%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

4.68%

Compounded annual net profit growth over 5 years

Pfizer Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for PFIZER — calculated from daily price history

44RSI 14
Neutral — RSI 44

Momentum is balanced — neither overbought nor oversold.

SMA 50
4762
▼ Price below SMA 50 — Short-term bearish
SMA 200
4981
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
22K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Pfizer Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Pfizer Ltd (PFIZER) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Pfizer Ltd

About PFIZER (Pfizer Ltd)

Pfizer Ltd is a significant player in the pharmaceutical sector, dedicated to the development, production, and global distribution of a diverse range of medical solutions. The comp...any's operations encompass the entire pharmaceutical value chain, from pioneering research and cutting-edge manufacturing to strategic marketing and widespread product availability. Pfizer Ltd demonstrates a strong commitment to addressing critical healthcare needs across numerous therapeutic areas, ensuring access to essential medications for patients worldwide. Through robust supply chains and collaborative partnerships, Pfizer Ltd strives to deliver impactful healthcare solutions, contributing to improved patient outcomes and overall public health. The corporation maintains stringent quality control standards throughout its processes, guaranteeing the safety and efficacy of its products and upholding its reputation as a trusted provider of pharmaceutical interventions. Pfizer Ltd distinguishes itself through its comprehensive portfolio of pharmaceutical products, targeting a wide spectrum of medical conditions and patient demographics. The company's offerings span critical therapeutic categories, including treatments for neurological disorders, cardiovascular diseases, oncological ailments, and infectious diseases. Pfizer Ltd maintains a strong presence in specialized areas such as hormone therapies, pain management, and urological health. Furthermore, the company recognizes the importance of preventative care, offering a range of vaccines and nutritional supplements to promote overall well-being. By catering to diverse medical needs, Pfizer Ltd aims to provide integrated healthcare solutions that improve the quality of life for individuals across different age groups and health conditions. This broad approach reflects the company's commitment to addressing the evolving healthcare challenges of modern society. Pfizer Ltd actively engages with healthcare professionals and institutions to foster collaboration and ensure the responsible use of its pharmaceutical products. The company is dedicated to providing comprehensive information and resources to support informed decision-making in patient care. Pfizer Ltd invests in ongoing research and development to discover and deliver innovative treatments for unmet medical needs. The company also actively participates in public health initiatives, working alongside governments and organizations to improve access to healthcare and promote disease prevention. With a strong focus on ethical practices and scientific rigor, Pfizer Ltd strives to uphold its commitment to improving global health and making a positive impact on the lives of patients worldwide.

Company Details

Symbol:PFIZER
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Ms. Meenakshi Nevatia
MD, CEO & Director
Mr. Prajeet Nair C.S.
Director of Corporate Services, Company Secretary & Compliance Officer
Mr. Pazhania Pillai Rengan
Whole-Time Director & Executive Director of Plant Operations

PFIZER Share Price: Frequently Asked Questions

What is the current share price of Pfizer Ltd?

Pfizer Ltd (PFIZER) trades at ₹4493.50 on NSE and BSE. Market cap ₹22.74K (Cr). Educational data only.

What is the P/E ratio of Pfizer Ltd?

Pfizer Ltd has a P/E of 32.18x vs industry average 31.77x.

What is the Bull Run score for Pfizer Ltd?

Pfizer Ltd has a Bull Run score of 55/100 based on 25+ financial parameters.

Does Pfizer Ltd pay dividends?

Pfizer Ltd has a dividend yield of 0.70%. Past dividends don't guarantee future payments.

What is the ROE of Pfizer Ltd?

Pfizer Ltd has ROE of 16.40%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Pfizer Ltd?

Pfizer Ltd has debt-to-equity of 0.01.

Is Pfizer Ltd a good investment?

Bull Run gives Pfizer Ltd a score of 55/100. This is not investment advice — consult a SEBI-registered advisor.